Progressive Lesion Type is Predictive of Post-progression Survival in First-line Chemoimmunotherapy for Non-small Cell Lung Cancer
Date
2026
Authors
Gao, Y.
Li, L.X.
Rowland, A.
Karapetis, C.S.
Parent, N.
Kichenadasse, G.
Hopkins, A.M.
Sorich, M.J.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Cancer Letters, 2026; 639:218191-1-218191-4
Statement of Responsibility
Yuan Gao, Lee X. Li, Andrew Rowland, Christos S. Karapetis, Natalie Parent, Ganessan Kichenadasse, Ashley M. Hopkins, Michael J. Sorich
Conference Name
Abstract
The revised Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) marked a significant advancement in the standardised assessment of solid tumours [1]. To evaluate treatment response and prognosis comprehensively, RECIST 1.1 incorporates target, non-target, and new lesions to describe tumour dynamics [1]. However, a key limitation of RECIST 1.1 is that it does not consider lesion-level heterogeneity and the lesion type(s) (i.e. existing lesions, new lesions, or both) causing progression [1]. Prior studies have shown that patients progressing with new metastatic lesions had nearly double the mortality risk compared to those with progression limited to pre-existing lesions [[2], [3], [4]]. Moreover, progression involving multiple lesion types has been associated with significantly worse post-progression survival than progression involving a single lesion type [4,5]. Nonetheless, RECIST 1.1 classifies all such progression events uniformly as progressive disease (PD), limiting its value in clinical prognostication.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2025 Published by Elsevier